Intravitreal Anti–Vascular Endothelial Growth Factor Cost Savings Achievable with Increased Bevacizumab Reimbursement and Use
David B. Glasser, Ravi Parikh, Flora Lum, George A. Williams
Topics & Concepts
MedicineAfliberceptBevacizumabReimbursementMedicare Part BRanibizumabPopulationInternal medicinePaymentFinanceHealth careChemotherapyBusinessEnvironmental healthEconomicsEconomic growthRetinal Diseases and TreatmentsRetinopathy of Prematurity StudiesOphthalmology and Visual Impairment Studies